TEVERELIX-TFA COMPOSITION
The present invention relates to a teverelix-TFA composition having a molar ratio of teverelix to trifluoroacetate composition of at least 1:2.4 and at or below 1:2.8. Such a molar ratio will prevent undesirable gel-formation and provide a homogenous suspension, whereby a unique bioavailablity of te...
Saved in:
| Main Authors | , |
|---|---|
| Format | Patent |
| Language | English French German |
| Published |
12.05.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | The present invention relates to a teverelix-TFA composition having a molar ratio of teverelix to trifluoroacetate composition of at least 1:2.4 and at or below 1:2.8. Such a molar ratio will prevent undesirable gel-formation and provide a homogenous suspension, whereby a unique bioavailablity of teverelix is obtained. |
|---|---|
| AbstractList | The present invention relates to a teverelix-TFA composition having a molar ratio of teverelix to trifluoroacetate composition of at least 1:2.4 and at or below 1:2.8. Such a molar ratio will prevent undesirable gel-formation and provide a homogenous suspension, whereby a unique bioavailablity of teverelix is obtained. |
| Author | POLAND, Guy BOUTIGNON, François |
| Author_xml | – fullname: POLAND, Guy – fullname: BOUTIGNON, François |
| BookMark | eNrjYmDJy89L5WSQDHENcw1y9fGM0A1xc1Rw9vcN8A_2DPH09-NhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfGuAcYWhubmphaOhsZEKAEAuyshqA |
| ContentType | Patent |
| DBID | EVB |
| DatabaseName | esp@cenet |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: EVB name: esp@cenet url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Chemistry Sciences |
| DocumentTitleAlternate | COMPOSITION DE TÉVÉRÉLIX-TFA TEVERELIX-TFA-ZUSAMMENSETZUNG |
| ExternalDocumentID | EP3817758A1 |
| GroupedDBID | EVB |
| ID | FETCH-epo_espacenet_EP3817758A13 |
| IEDL.DBID | EVB |
| IngestDate | Fri Sep 06 06:11:36 EDT 2024 |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Language | English French German |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-epo_espacenet_EP3817758A13 |
| Notes | Application Number: EP20190739941 |
| OpenAccessLink | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210512&DB=EPODOC&CC=EP&NR=3817758A1 |
| ParticipantIDs | epo_espacenet_EP3817758A1 |
| PublicationCentury | 2000 |
| PublicationDate | 20210512 |
| PublicationDateYYYYMMDD | 2021-05-12 |
| PublicationDate_xml | – month: 05 year: 2021 text: 20210512 day: 12 |
| PublicationDecade | 2020 |
| PublicationYear | 2021 |
| RelatedCompanies | Antev Limited |
| RelatedCompanies_xml | – name: Antev Limited |
| Score | 3.3262994 |
| Snippet | The present invention relates to a teverelix-TFA composition having a molar ratio of teverelix to trifluoroacetate composition of at least 1:2.4 and at or... |
| SourceID | epo |
| SourceType | Open Access Repository |
| SubjectTerms | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| Title | TEVERELIX-TFA COMPOSITION |
| URI | https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20210512&DB=EPODOC&locale=&CC=EP&NR=3817758A1 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1NS8Mw9DGm6G46FesXPUhvRdamX4ciW5qyiV3LrKO30dQUdtmG6_Dv-xK66UUv4ZFAPh55ed8vAI--JTynJtzEyyKLale2WQY8MMvKEkHl8bL2Ze5wMnXH7-SlcIoOLPe5MKpO6JcqjogUVSG9N-q93vwYsSIVW7l94kvsWj_HeRgZrXaM-gsyMCMahSxLo5QalCJkTGehLESHovEQFaUjlKI9Gf3F5iOZlLL5zVHiMzjOcLJVcw4dserDKd1_vNaHk6T1dyPYkt72ArSczdmMvU4KM4-HOk2TLH2bSAPTJegxy-nYxDUWh_MsWHbYjX0FXVTzxTXoLspmEmHEIR-kLn3fkU3pumJAeBXYGmh_TnPzz9gt9CRipMd7YN1Bt_nciXtkpA1_UCj4BqdzdDY |
| link.rule.ids | 230,309,783,888,25578,76884 |
| linkProvider | European Patent Office |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NT4MwFH9ZpnHedGrETw6GGzFjhcGBmA1KQPnKxIUboawku8zFYfz3fSVsetFL07RJP176-r76fgV4MDU-0WvCVDwsAlS7GqulxSy1rDRuVRNW1qbIHY5iw38jz7me92C1y4VpcUK_WnBE5KgK-b1p7-vNjxPLbd9Wbh_ZCpven7zMdpXOOkb7BQWY4s5smiZu4iiOgzUlntsCiA5V4ykaSgeoYZsCZp8uZiIpZfNbongncJjiYOvmFHp8PYSBs_t4bQhHURfvxmrHetszkDK6oHMaBrmaeVPZSaI0eQ2Eg-kcZI9mjq_iHMV-PwVN96sZX0AfzXx-CbKBupkgGNHJktSlaeqiKA2DjwirrLEE0p_DXP3Tdw8DP4vCIgzil2s4FkQS0e-RdgP95uOT36JQbdhdS45vQeF3Jg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=TEVERELIX-TFA+COMPOSITION&rft.inventor=POLAND%2C+Guy&rft.inventor=BOUTIGNON%2C+Fran%C3%A7ois&rft.date=2021-05-12&rft.externalDBID=A1&rft.externalDocID=EP3817758A1 |